Compare BTG & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | HIMS |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Nursing Services |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.9B |
| IPO Year | N/A | N/A |
| Metric | BTG | HIMS |
|---|---|---|
| Price | $5.41 | $19.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 13 |
| Target Price | $6.00 | ★ $38.41 |
| AVG Volume (30 Days) | ★ 50.2M | 27.9M |
| Earning Date | 02-18-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | ★ 20.76 |
| EPS | 0.15 | ★ 0.54 |
| Revenue | ★ $2,507,049,000.00 | $2,210,958,000.00 |
| Revenue This Year | $68.08 | $62.27 |
| Revenue Next Year | $22.77 | $17.90 |
| P/E Ratio | ★ $35.14 | $36.01 |
| Revenue Growth | 30.97 | ★ 78.02 |
| 52 Week Low | $2.50 | $16.35 |
| 52 Week High | $5.94 | $72.98 |
| Indicator | BTG | HIMS |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 19.93 |
| Support Level | $4.71 | $28.33 |
| Resistance Level | $5.15 | $27.77 |
| Average True Range (ATR) | 0.31 | 2.34 |
| MACD | -0.02 | -0.72 |
| Stochastic Oscillator | 58.33 | 20.80 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.